Skip to main content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

Health and Quality of Life Outcomes 1/2012

The Barretos short instrument for assessment of quality of life (BSIqol): development and preliminary validation in a cohort of cancer patients undergoing antineoplastic treatment

Health and Quality of Life Outcomes > Ausgabe 1/2012
Carlos Eduardo Paiva, Fernanda Capella Rugno, Bianca Sakamoto Ribeiro Paiva
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7525-10-144) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CEP and BSRP conceptualized the study and developed the questionnaire. CEP and FCR obtained the data. CEP analyzed the data. All authors provided input on the interpretation and they read and approved of the final draft of the manuscript.



To be clinically useful, an instrument assessing health-related quality of life (HRQOL) should be easy to understand and quick to answer. Few instruments have been designed to be short, simple, and easily understandable by patients from all educational levels. The aim of the present study was to evaluate the psychometric properties of a brief general instrument developed to assess HRQOL.


Results from a preliminary study regarding the initial development of the Barretos Short Instrument for Assessment of Quality of Life (BSIqol) with 80 cancer patients are presented. Out of all the patients, 59 completed the BSIqol on two occasions in order to evaluate the reproducibility test-retest. Validity analyses were done comparing scores from BSIqol with EORTC QLQ-C30 and Edmonton Symptom Assessment System (ESAS). In addition, BSIqol scores were analyzed in function of ECOG-PS, work activity, and financial income.


BSIqol demonstrated good internal consistency (Cronbach's α = 0.79) and adequate test-retest reliability, with intraclass coefficient correlation (ICC) varying from 0.736 to 0.946. There were adequate correlations between scores of BSIqol, EORTC QLQ-C30 and ESAS. The BSIqol was capable of discriminating between clinical subgroups, with different ECOG-PS and work activity. Patients completed the BSIqol in a median time <2 min. Only one patient reported some difficulty to answer the instrument.


BSIqol seems to be a straightforward and useful instrument for rapidly assessing HRQOL from cancer patients. Further studies are necessary to evaluate BSIqol in different populations and also to assess its responsiveness and define its minimal clinically important differences.
Additional file 1:Figure S1. The Barretos short instrument for assesment of quality of life (BSIqol) in Portuguese – original instrument. (JPEG 619 KB)
Additional file 2:Figure S2. The Barretos short instrument for assesment of quality of life (BSIqol) in English – translated instrument. (PDF 261 KB)
Additional file 3:Table S1. Patient characteristics. (DOCX 16 KB)
Additional file 4:Table S2. Spearman correlation analysis between BSIqol domains and Performance Status and financial income. (DOCX 14 KB)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Health and Quality of Life Outcomes 1/2012 Zur Ausgabe